InTech uses cookies to offer you the best online experience. By continuing to use our site, you agree to our Privacy Policy.

Medicine » Infectious Diseases » "Practical Management of Chronic Viral Hepatitis", book edited by Gaetano Serviddio, ISBN 978-953-51-1109-2, Published: May 29, 2013 under CC BY 3.0 license. © The Author(s).

Chapter 6

Current Concepts on Management of Chronic Hepatitis B

By Teresa Santantonio and Massimo Fasano
DOI: 10.5772/54759

  1. D Lavanchy, Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 20041197107

  2. G Fattovich, Natural history and prognosis of hepatitis B. Semin Liver Dis 2003234758

  3. C. K Hui, N Leung, S. T Yuen, H. Y Zhang, K. W Leung, L Lu, et alNatural History and Disease Progression in Chinese Chronic Hepatitis B Patients in Immune-tolerant Phase. Hepatology 200746395401

  4. M. R Brunetto, F Oliveri, P Colombatto, F Moriconi, P Ciccorossi, B Coco, et alHepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010139483490

  5. G Raimondo, J. P Allain, M. R Brunetto, M. A Buendia, D. S Chen, M Colombo, et alStatements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 200849652657

  6. A Zerbini, M Pilli, C Boni, P Fisicaro, A Penna, P Di Vincenzo, et alThe characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 200813414701481

  7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 201257167185

  8. A. S Lok, B. J McMahon, Chronic hepatitis B: Update 2009. Hepatology (2009). 50661662

  9. Y. F Liaw, N Leung, J. H Kao, T Piratvisuth, E Gane, K. H Han, et alAsian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 20082263283

  10. L Castera, Non invasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 201214212931302

  11. G Fattovich, F Bortolotti, F Donato, Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 200848335352

  12. H. I Yang, S. N Lu, Y. F Liaw, S. L You, C. A Sun, L. Y Wang, et alHepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002347168174

  13. U. H Iloeje, H. I Yang, J Su, C. L Jen, S. L You, S. J Chen, et alPredicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006130678686

  14. C. J Chen, H. I Yang, J Su, C. L Jen, S. L You, S. N Lu, et alRisk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 20062956573

  15. M Van Zonneveld, H. J Flink, E Verhey, H Senturk, S Zeuzem, U. S Akarca, et alThe safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 20052111631171

  16. G. K Lau, T Piratvisuth, K. X Luo, P Marcellin, S Thongsawat, G Cooksley, et alPeginterferon alpha-2a, Lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 200535226822695

  17. G. K Lau, T Piratvisuth, H. X Luo, P Marcellin, S Thongsawat, G Cooksley, et alDurabilty of response and occurrence of late response to peginterferon alpha-2a (40KD) [Pegasys] one year post-treatment in patients with HBeAg-posive chronic hepatitis B. J Hepatol 2006Abs 50.

  18. E. H Buster, H. J Flink, Y Cakaloglu, K Simon, J Trojan, F Tabak, et alSustained HBeAg and HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b. Gastroenterology 2008135459467

  19. Buster EHCJ, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 200913720022009

  20. T Piratvisuth, et alSustained Immune Control 1 Year Post-Treatment With Peginterferon Alfa-2a [40KD] (PEGASYS) is Durable up to 5 Years Post-Treatment and is Associated With a High Rate of HBsAg Clearance in HBeAg-Negative Chronic Hepatitis B. Hepatol Int 2010Abs210.

  21. P Marcellin, G. K Lau, F Bonino, et alPeginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 200435112061217

  22. P Piccolo, I Lenci, L Demelia, F Bandiera, M. R Piras, G Antonucci, et alA randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 20091411651174

  23. Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol. 201010517621769

  24. Y. F Liaw, J. D Jia, H. L Chan, K. H Han, T Tanwandee, W. L Chuang, et alShorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 20115415911599

  25. Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, et al. Randomised study comparison 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2012Epub ahead of print]

  26. Janssen HLA, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005365123129

  27. M. J Sonneveld, V Rijckborst, S Zeuzem, E. J Heathcote, K Simon, H Senturk, S. D Pas, B. E Hansen, H Janssen, Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2012566774

  28. T. C Tseng, M. L Yu, C. J Liu, C. L Lin, Y. W Huang, C. S Hsu, et alEffect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon alpha-2a therapy. Antivir Ther 201116629637

  29. M. J Sonneveld, V. W Wong, A. M Woltman, G. L Wong, Y Cakaloglu, S Zeuzem, et alPolymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012142513520

  30. X Wu, Z Xin, X Zhu, L Pan, Z Li, H Li, et alEvaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 201293297300

  31. P Lampertico, M Viganò, C Cheroni, F Facchetti, F Invernizzi, V Valveri, et alIL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B. Hepatology 2012Epub ahead of print]

  32. M. J Sonneveld, V Rijckborst, C. A Boucher, B. E Hansen, H. L Janssen, Prediction of sustained response to peginterferon alpha-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 20105212511257

  33. T Piratvisuth, P Marcellin, M Popescu, H. P Kapprell, V Rothe, Z. M Lu, Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2011Epub ahead of print]

  34. V Rijckborst, B. E Hansen, Y Cakaloglu, P Ferenci, F Tabak, M Akdogan, et alEarly on-treatment prediction of response to peginterferon alpha-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 201052454461

  35. V Rijckborst, B. E Hansen, P Ferenci, M. R Brunetto, F Tabak, Y Cakaloglu, et alValidation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 20125610061011

  36. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 201051422430

  37. D Shouval, C. L Lai, T. T Chang, A Gadano, S. S Wu, W Halota, et alThree years of entecavir (ETV) re-treatment of HBeAg(-) ETV patients who previously discontinued ETV treatment: results from study ETV-901. Hepatology 2008Abs 927.

  38. P Marcellin, E. J Heathcote, M Buti, E Gane, R. A De Man, Z Krastev, et alTenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 200835924422455

  39. E. J Heathcote, P Marcellin, M Buti, E Gane, R. A De Man, Z Krastev, et alThree-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 201114013243

  40. P Marcellin, M Buti, E. J Gane, Z Krastev, R Flisiak, G Germanidis, et alFive years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011Suppl 1):1011A-1012A. Abs 1375.

  41. D. J Tenney, R. E Rose, C. J Baldick, K. A Pokornowski, B. J Eggers, J Fang, et alLong-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 20094915031514

  42. A Snow-lampart, B Chappell, M Curtis, Y Zhu, F Myrick, J Schawalder, et alNo resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 201153763773

  43. M Manns, U. S Akarca, T. T Chang, W Sievert, S-K Yoon, N Tsai, et alLow rates of nucleos(t)ide-associated adverse events in the long-term experience with entecavir. J Hepatol 2010S393. Abs 1016.

  44. P Lampertico, R Soffredini, F Invernizzi, M Vigano, F Facchetti, E Minola, et alMaintained viral suppression and excellent safety profile of Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B: a 4-year field practice, multicenter study. J Hepatol 2012S206. Abs 522.

  45. Seto WK, Lai CL, Fung J, Yuen DKH, Wong M, Yuen MF. Outcome of 4-year treatment of entecavir for treatment-naive chronic hepatitis B. J Hepatol 2011S301. Abs 748.

  46. M Buti, R. M Morillas, M Prieto, M Diago, J Pérez, R Solà, ET ALEfficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. Eur J Gastroenterol Hepatol 201224535542

  47. R Zoutendjik, J. G Reijnders, A Brown, et alEntecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virologic response. Hepatology 201154443451

  48. R Zoutendijk, J Reijnders, F Zoulim, B Brown, D Mutimer, K Deterding, et alVirological response to Entecavir is associated with a better clinical outcome in chronic hepatitis B patients. Gut 2012Epub ahead of print]

  49. P Lampertico, R Soffredini, M Vigano, C Yurdaydin, R Idilman, G. V Papatheodoridis, et alTenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months. J Hepatol 2012S208. Abs 525.

  50. F Zoulim, S Locarnini, Management of treatment failure in chronic hepatitis B. J Hepatol 2012Suppl 1:S112122